INVO Fertility Q1 2025 revenue up 4% but net loss widens to $17.4M on $14.6M impairment

INVO Fertility, Inc.

2025-Q1 EPS reported -$12.53 revenue$1,637,185

Revenue $1.64M, +4% YoY; clinic revenue from consolidated centers +5% to $1.62M.
Net loss of $17.4M vs $1.6M; includes $14.6M non-cash impairment on NAYA Therapeutics assets.
Adjusted EBITDA loss widened to $(606,551) from $(427,467) in prior year.
Company refocuses on fertility after April 2025 decision to divest majority stake in NAYA TX.
CEO cites supportive policy shifts and aims for cash flow break-even through clinic expansion.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.